News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
FOLFOXIRI only adds 1.6 months PFS but increases toxicity significantly – Enrique Soto
Photo from Enrique Soto/Twitter
Jun 19, 2023, 19:57

FOLFOXIRI only adds 1.6 months PFS but increases toxicity significantly – Enrique Soto

Interesting results  

  • FOLFOXIRI only adds 1.6 months PFS but increases toxicity significantly (7 toxic deaths)
  • Panitumumab sucks   
  • My takeaway: Two drugs + bev still best choice across the board (even no bev for some patients).

Source: Enrique Soto/Twitter

Enrique Soto FOLFOXIRI Oncology Panitumumab PFS The Lacet Oncology toxicity
Special Coverage
Insight
Aug 8, 2025, 08:56
MD Anderson Research Highlights
Blog
Aug 8, 2025, 08:51
David Ochoa: Join Us in Making a Difference in the Lives of Children and Families
Blog
Aug 8, 2025, 08:51
Gustavo Viani: Salvage RT Alone or With Hormonal Therapy?
Blog
Aug 8, 2025, 08:38
Liyana Rafeek: The Future of Lymphoma Care
Insight
Aug 8, 2025, 07:59
Adrian Pogacian: Fear Comes as Natural, But Hope is Learned!
Drugs
Aug 8, 2025, 07:08
Adagrasib (Krazati) Updates 2025: Uses in Cancer, Side Effects, Dosages, Expectations, and More
Career
Aug 8, 2025, 06:20
Joseph Contessa Selected as the Chair of Radiation Oncology at Rutgers Cancer Institute
Dialogues
Aug 8, 2025, 06:16
Accelerating Cancer Drug Development with AI: Interview with Dr. Jen-Tang (JT) Lu from Vysioneer
Blog
Aug 8, 2025, 06:08
Better-Targeted Therapies for Patients with Acute Myeloid Leukemia - IU Simon Comprehensive Cancer Center
Blog
Aug 8, 2025, 05:59
The Silver Jubilee of the Townsville to Cairns Bike Ride: Raising Funds for Childhood Cancer - Children's Cancer Institute
Insight
Aug 8, 2025, 05:47
FASCO 2025: 97 Voices, One Mission: Part 2
Science
Aug 8, 2025, 05:44
Yan Leyfman: Turning Paradoxical Biology Into Precision Immunotherapy Opportunities